PHAT — Phathom Pharmaceuticals, Inc.

Summary of Phathom Pharmaceuticals Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $49.5 million for Q3 2025, representing a 25% increase quarter-over-quarter and exceeding expectations of approximately $47 million.
• Operating Expenses: Cash operating expenses were $49.3 million, a 43% reduction from Q2 2025 and a 50% reduction from Q1 2025. This was below the previously set target of $60 million for Q3.
• Cash Usage: Decreased to less than $15 million, down 77% from Q2.
• Gross Profit Margin: Approximately 87%, consistent with previous quarters.
• Filled Prescriptions: 221,000 prescriptions in Q3, with 144,000 being covered scripts (up 23% from Q2) and 77,000 cash prescriptions (up 38% from Q2).

2. Strategic Updates and Business Highlights

• Leadership Changes: Sanjeev Narula joined as Chief Financial and Business Officer, and Nancy Phelan as SVP of Marketing and Analytics.
• Focus Shift: The company is concentrating on gastroenterology, with a strategy to deepen relationships with gastroenterologists rather than broadening outreach to primary care physicians (PCPs).
• Sales Force Realignment: Territories have been restructured to better target gastroenterologists, with plans to increase the sales force from 280 to approximately 300 representatives by Q1 2026.
• Clinical Trials: Initiated a Phase II trial for Eosinophilic Esophagitis (EoE), with expectations to report top-line results in 2027.

3. Forward Guidance and Outlook

• Updated Revenue Guidance: Narrowed to $170 million to $175 million for the full year 2025.
• Operating Expenses Guidance: Expected to remain below $55 million in Q4, despite increased expenses from the EoE trial.
• Long-term Profitability: The company aims to achieve operating profitability in 2026, excluding stock-based compensation, with confidence in revenue growth outpacing cash operating expenses.

4. Challenges and Points of Concern

• Sales Force Transition: The realignment of the sales force may cause temporary disruptions in Q4, potentially impacting revenue growth.
• Market Penetration: While there is strong growth in gastroenterology, the company acknowledges the challenge of changing long-standing prescribing habits among physicians.
• Gross to Net Guidance: The gross to net ratio is expected to remain at the lower end of the previously guided range of 55% to 65%, indicating potential pressures on margins.

5. Notable Q&A Insights

• Prescription Growth: Analysts questioned the anticipated slowdown in prescription growth for Q4, with management indicating that the sales force transition could impact this metric.
• Marketing Strategy: There is confidence that the pause in direct-to-consumer advertising will not adversely affect growth, as the focus remains on effective sales strategies.
• Patient Adoption: Management highlighted that while initial adoption among gastroenterologists is high, the challenge lies in increasing the frequency of prescriptions, which requires ongoing engagement and education.
• Cash-Pay vs. Covered Scripts: The company does not actively manage the mix of cash-pay and covered prescriptions, focusing instead on overall growth in both categories.

Overall, Phathom Pharmaceuticals reported a strong quarter with significant revenue growth and cost reductions, while strategically pivoting towards gastroenterology. However, challenges remain in sales force transition and changing physician prescribing habits. The outlook for 2026 appears positive, with expectations for operating profitability.